机构：[1]Kunming Research Center for Molecular Medicine, Kunming University, Kunming 650214, People’s Republic of China[2]Department of Endocrinology, Second Affiliated Hospital of Kunming Medical University, Kunming 650500, People’s Republic of China[3]School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, People’s Republic of China[4]Department of Emergency Medicine and Intensive Care Unit, First Affiliated Hospital of Kunming Medical University, Kunming 650032, People’s Republic of China昆明医科大学附属第一医院[5]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, People’s Republic of China
Osteoporosis is a systemic and metabolic bone disease. New drugs with good curative effect, fewer side effects, and high safety need to be developed urgently. Recently, simvastatin has been used to treat osteoporosis more frequently; however, its clinical effect and treatment mechanism are still unknown. With the use of animal models, the treatment effectiveness of simvastatin on experimental osteoporosis was investigated and the functional mechanism was preliminarily explored. The results show that simvastatin significantly increased the mechanical parameters such as maximum load, stiffness, and energy-absorbing capacity, and improved the microarchitecture. They indicated that the antiosteoporosis activity of simvastatin may be due to the promotion of proliferation and differentiation of osteoblasts. Simvastatin was effective in treating experimental osteoporosis. This study provides necessary experimental evidence for the clinical application of simvastatin in osteoporosis treatment.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81060361]; Natural Science Foundation of Yunnan Province, ChinaNatural Science Foundation of Yunnan Province [2012FA002, 2010ZC169, 2012HB043]; Department of Education, Yunnan province, China [ZD2012006]; Natural Science Foundation of Kunming City, China [10S090202, 2012-01-01-A-R-07-0006, 2014-05-06-A-R-07-0005]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|3 区医学
小类|4 区内分泌学与代谢4 区医学：研究与实验
最新[2023]版：
大类|3 区医学
小类|3 区医学：研究与实验4 区内分泌学与代谢
JCR分区：
出版当年[2015]版：
Q3MEDICINE, RESEARCH & EXPERIMENTALQ3ENDOCRINOLOGY & METABOLISM
最新[2023]版：
Q3MEDICINE, RESEARCH & EXPERIMENTALQ3ENDOCRINOLOGY & METABOLISM
第一作者机构：[1]Kunming Research Center for Molecular Medicine, Kunming University, Kunming 650214, People’s Republic of China[2]Department of Endocrinology, Second Affiliated Hospital of Kunming Medical University, Kunming 650500, People’s Republic of China[3]School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, People’s Republic of China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Lifen Dai,Ming Xu,Haiying Wu,et al.The functional mechanism of simvastatin in experimental osteoporosis[J].JOURNAL OF BONE AND MINERAL METABOLISM.2016,34(1):23-32.doi:10.1007/s00774-014-0638-y.
APA：
Lifen Dai,Ming Xu,Haiying Wu,Lanjie Xue,Dekai Yuan...&Min Hu.(2016).The functional mechanism of simvastatin in experimental osteoporosis.JOURNAL OF BONE AND MINERAL METABOLISM,34,(1)
MLA：
Lifen Dai,et al."The functional mechanism of simvastatin in experimental osteoporosis".JOURNAL OF BONE AND MINERAL METABOLISM 34..1(2016):23-32
